Curatis to Boost Revenue with Phoenix Labs Partnership

Curatis Holding AG has announced a significant distribution agreement with Phoenix Labs, based in Ireland. The contract involves the distribution of four products related to pain management and urology in Switzerland, effective from October 2025. These products previously generated CHF 5 million in revenue within Switzerland for the year 2024.

Curatis, holding the marketing authorization, will manage regulatory and quality control along with pharmacovigilance services in Switzerland for these products. This partnership is projected to enhance Curatis' annual revenue by up to CHF 5 million, marking a notable expansion in their distribution business.